The Emergence of a Post COVID-19 Risk Mitigation Strategy Over the last few decades, pharma companies serving the U.S. market have moved most of their production and API manufacturing overseas. There were obvious incentives at the time. Offshore operations could deliver significant cost savings, even after factoring in the expense of shipping product to the[…]
Reshoring Early-Stage Pharma
blog, Supply Chain Tags: APIsCOVID-19reshoringrisk mitigationsupply chain Feb 28, 2021
Can the U.S. Stop Buying Drugs from China?
blog, Supply Chain Tags: ChinaCOVID-19risk managementsupply chain Oct 04, 2020
The SARS-CoV-2 pandemic has drawn significant attention to just how much US pharmaceutical manufacturers rely on manufacturers outside the United States, both for drug substances and finished dosage drugs. It also has demonstrated the risks associated with global supply chains that are overly reliant on specific regions such as China and India, which may be[…]
A Look at Reshoring Drug Manufacturing: A Q&A With LGM Pharma’s Hamilton Lenox
blog, Supply Chain Tags: ChinaCOVID-19reshoringsupply chain Jun 08, 2020
When SARS-CoV-2 arrived on American shores this Spring, concerns about overextended drug supply chains already were circulating. The issues at hand weren’t new, by any stretch. Environmental, quality and political actions all had impacted drug imports in the last half-dozen years, causing drug shortages and C-suite anxiety. The global pandemic – and the resultant (albeit[…]
